Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized linezolid dosing and TDM practice study
ChiCTR2600132548Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of linezolid in bacterial disease and Gram-positive bacterial infection, sponsored by Huashan Hospital. Primary endpoint: Linezolid target attainment rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
linezolid
03
Conditions
bacterial diseaseGram-positive bacterial infection
Beyond the preview
Go deeper on ChiCTR2600132548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132548.